How Novartis ’ data manipulation case is a cautionary tale for transparency

“Seeing something and saying something” can be applied to the life sciences when a lack of transparency could result in a company facing stiff regulatory action.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals